Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Estimated Market Size of the Corneal Endothelial Dystrophy Market In 2029?
In recent times, the market size of corneal endothelial dystrophy has seen robust growth. It is projected to expand from $170.96 billion in 2024 to $184.84 billion in 2025, reflecting a compound annual growth rate (CAGR) of 8.1%. This growth during the historic period is driven by factors such as increased healthcare spending, a rise in the number of corneal endothelial dystrophy cases, an aging global population, a steadily increasing rate of eye diseases, and an escalating prevalence of corneal disorders.
In the coming years, the corneal endothelial dystrophy market is projected to experience significant growth, reaching a value of$250.98 billion by 2029, with a compound annual growth rate (CAGR) of 7.9%. The expansion anticipated in this period can be linked to an increase in corneal blindness in developing nations, a rise in eye health consciousness, growing need for corneal transplants, enhanced healthcare facilities, and a higher incidence of chronic diseases. The main trends for the forecast period includes progression in regenerative therapies, advancements in healthcare technology, improvements in diagnostic methods, technological progress in ophthalmic lasers, and the emergence of advanced technologies.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21158&type=smp
Which Primay Drivers Are Accelerating Growth in the Corneal Endothelial Dystrophy Market?
The increase in demand for corneal transplants is expected to positively impact the progress of the corneal endothelial dystrophy market. A medical procedure wherein a damaged or diseased cornea is substituted with a healthy one from a donor to improve eyesight and overall eye health is known as corneal transplantation. The need for these procedures is heightened due to the increase in corneal disease rates, better surgical methods, and higher organ donation frequencies. Corneal endothelial dystrophy is tackled through corneal transplants, substituting the impaired endothelium with suitable donor tissue to regain corneal clarity, decrease edema, and enhance eye sight. For instance, data from the US-based Eye Bank Association of America revealed that in 2023, domestic keratoplasty procedures, a type of corneal transplant, experienced a 2.7% increase, jumping from 49,597 in 2022 to 50,925 in 2023. Therefore, the demand for corneal transplants is seen to be fueling the corneal endothelial dystrophy market’s expansion.
Which Primary Segments of the Corneal Endothelial Dystrophy Market Are Driving Growth and Industry Transformations?
The corneal endothelial dystrophymarket covered in this report is segmented –
1) By Treatment: Phototherapeutic Keratectomy; Amniotic Membrane Transplants; Anterior Stromal Puncture; Conjunctival Flaps
2) By Disease Type: Congenital Hereditary Endothelial Dystrophy 1; Congenital Hereditary Endothelial Dystrophy 2; Posterior Polymorphous Corneal Dystrophy; Fuchs Endothelial Corneal Dystrophy
3) By Diagnosis: Cornea Examination And Grading; Corneal Tomography; Corneal Pachymetry; Corneal Cell Count
4) By End-User: Hospitals; Clinics; Other End Users
Subsegments:
1) By Phototherapeutic Keratectomy: Excimer Laser Therapy; Corneal Reshaping
2) By Amniotic Membrane Transplants: Fresh Amniotic Membrane Transplant; Cryopreserved Amniotic Membrane Transplant
3) By Anterior Stromal Puncture: Manual Technique; Laser-Assisted Technique
4) By Conjunctival Flaps: Partial Flap Technique; Full Flap Technique
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=21158&type=smp
Which Regions Are Key Players in the Growth of the #Which Primay Drivers Are Accelerating Growth in the Corneal Endothelial Dystrophy Market?# Market?
North America was the largest region in the corneal endothelial dystrophy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the corneal endothelial dystrophy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Which Technological Trends Are Reshaping the Corneal Endothelial Dystrophy Industry Dynamics?
In an effort to cater to unfulfilled medical needs with new, minimally invasive alternatives which enhance patient results, key companies in the corneal endothelial dystrophy market are investing in the development of cutting-edge treatments like allogeneic cell therapy. This specific form of therapy involves utilizing cells sourced from a genetically distinct donor of the same species to treat the patient. In a notable example from September 2024, Aurion Biotech Inc., a clinical-stage biotech company from the U.S., introduced Vyznova (neltependocel) in Japan as a treatment for bullous keratopathy, a type of corneal endothelial disease. As a cell therapy developed by Aurion Biotech, Vyznova treats bullous keratopathy, a condition that impairs corneal endothelial cells and results in vision issues. It holds the distinction of being the first approved cell therapy for corneal endothelial disease and has received approval in Japan. Vyznova incorporates lab-grown corneal endothelial cells, which means a single donor can yield up to 1,000 doses. This revolutionary treatment presents a less intrusive alternative to corneal transplants, thus mitigating the lack of donor corneas and paving a novel path to restoring vision to patients afflicted with corneal diseases.
View the full report here:
https://www.thebusinessresearchcompany.com/report/corneal-endothelial-dystrophy-global-market-report
What Parameters Are Used to Define the Corneal Endothelial Dystrophy Market?
Corneal endothelial dystrophy is a genetic eye disorder that affects the cornea’s endothelium (the inner layer of cells), leading to progressive loss of corneal clarity. The condition is characterized by the degeneration of the endothelial cells responsible for maintaining proper fluid balance within the cornea.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21158
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model